Search Result

Results for "

LSDs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (18) Bcl-2 Family (1) Caspase (1) Dopamine Receptor (2) Estrogen Receptor/ERR (1) Fluorescent Dye (1) Glucosidase (2) HDAC (6) Histone Demethylase (78) Histone Methyltransferase (1) HSV (1) IAP (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Monoamine Oxidase (11) PD-1/PD-L1 (2) Phosphatase (1) ROS Kinase (1) TNF Receptor (1)
By Research Areas:	Cancer (72) Cardiovascular Disease (4) Endocrinology (1) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (10)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151192

LSD1/2-IN-3	Histone Demethylase	Cancer
LSD1/2-IN-3 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 11 nM instead of 7 μM for *LSD2. There is aberrant expression of LSD1* in cancer stem cells, LSD1/2-IN-1 inhibits *LSD1* cell proliferation .

HY-152032

LSD1-IN-23	Histone Demethylase	Cancer
LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of lysine specific demethylase 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC₅₀ value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) .

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent *LSD1* inhibitor. LSD1-IN-15 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM .

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent *LSD1* inhibitor. LSD1-IN-16 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM .

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent *LSD1* inhibitor. LSD1-IN-17 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM .

HY-155115

LSD1-IN-27	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-27 (Compound 5ac) is a *LSD1* inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .

HY-149978

LSD1-IN-26	Histone Demethylase Monoamine Oxidase Apoptosis Bcl-2 Family IAP Caspase	Cancer
LSD1-IN-26 (compound 12u) is a potent *LSD1* inhibitor, with an IC₅₀ of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC₅₀=1234.57 nM) and MAO-B (IC₅₀=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research .

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent *LSD1* inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent *LSD1* inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-100859

LSD1-IN-5
LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-100860

LSD1-IN-6	Histone Demethylase	Cancer
LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-151191

LSD1-IN-22	Histone Demethylase	Cancer
LSD1-IN-22 is a potent Lysine-specific demethylase 1 (LSD1) inhibitor with a K_i value of 98 nM. LSD1-IN-22 has anti-proliferative activity against certain cancer cells .

HY-149968

LSD1-IN-25	Histone Demethylase Apoptosis	Cancer
LSD1-IN-25 (Compound 9j) is a potent, selective and orally active *LSD₁* inhibitor with an IC₅₀ of 46 nM (K_i = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis .

HY-147697

LSD1-IN-21	Histone Demethylase TNF Receptor	Inflammation/Immunology Cancer
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated *LSD1* (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity .

HY-144673

LSD1-IN-12	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-12 (compound 2) is a potent *LSD1* inhibitor, with K_i values of 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), and 3.5 μM (MAO-B), respectively .

HY-12645

NCL1	Histone Demethylase	Cancer
NCL1 is a phenylcyclopropylamine (PCPA)-based Lysine-specific demethylase 1 (LSD1) inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC₅₀ values of 2.5 and 26 μM for LSD1 and LSD2, respectively .

HY-131970

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of *lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6), with anti-tumor activity. LSD*1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) .

HY-146440

LSD1/ER-IN-1	Histone Demethylase Estrogen Receptor/ERR Apoptosis	Cancer
LSD1/ER-IN-1 (compound 11g) is a potent ER and *LSD1* inhibitor, with an IC₅₀ of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC₅₀ of 8.79 μM .

HY-145861

LSD1-IN-14	Histone Demethylase Apoptosis	Cancer
LSD1-IN-14 is a potent and selective *LSD1* inhibitor (IC₅₀=0.89 μM). LSD1-IN-14 can significantly inhibit the proliferation of A549 and THP-1 cells and induce the apoptosis of tumor cells .

HY-160183

LSD1-IN-29

Histone Demethylase Cancer

LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

LSD1-IN-29	Histone Demethylase	Cancer
LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

HY-149213

LSD1-IN-24	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-24(compound 3S) is a selective *LSD1* inhibitor with IC₅₀ = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research .

HY-160191

LSD1-IN-30

Histone Demethylase Cancer

LSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC₅₀ value of 0.291 μM .

LSD1-IN-30	Histone Demethylase	Cancer
LSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC₅₀ value of 0.291 μM .

HY-146285

LSD1-IN-20	Histone Demethylase Histone Methyltransferase	Cancer
LSD1-IN-20 (compound 1) is a potent dual non-covalent *LSD1/G9a* inhibitor, with K_i values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.51 and 1.60 μM, respectively .

HY-112304

NCD38 TFA

Histone Demethylase Others

NCD38 TFA is a LSD1-selective inhibitor .

NCD38 TFA	Histone Demethylase	Others
NCD38 TFA is a *LSD1*-selective inhibitor .

HY-100546

*GSK-LSD1*
GSK-LSD1 is a *LSD1* inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

HY-149595

LSD1-UM-109	Histone Demethylase	Cancer
LSD1-UM-109 is a ighly potent and reversible *LSD1* inhibitor with an IC₅₀ of 3.1 nM. LSD1-UM-109 inhibits cell growth with IC₅₀ values of 0.6 nM in the MV4;11 acute leukemia cell line and 1.1 nM in the H1417 small-cell lung cancer cell line .

HY-146283

LSD1-IN-18	Histone Demethylase	Cancer
LSD1-IN-18 (compound 7) is a potent, non-covalent and selective *LSD1* inhibitor, with K_i of 0.156 μM and K_D of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.16 and 0.21 μM, respectively .

HY-146284

LSD1-IN-19	Histone Demethylase	Cancer
LSD1-IN-19 (compound 29) is a potent, non-covalent and selective *LSD1* inhibitor, with K_i of 0.108 μM and K_D of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.17 and 0.40 μM, respectively .

HY-100546A

*GSK-LSD1 dihydrochloride* 5 Publications Verification	Histone Demethylase Monoamine Oxidase	Cancer
GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.

HY-112623

Vafidemstat 1 Publications Verification ORY-2001	Histone Demethylase Monoamine Oxidase	Neurological Disease
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor .

HY-111048

Corin 1 Publications Verification	Histone Demethylase HDAC	Cancer
Corin is a dual inhibitor of histone lysine specific demethylase *(LSD1)* and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.

HY-18632A

GSK2879552 dihydrochloride Maximum Cited Publications 10 Publications Verification	Histone Demethylase	Cancer
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity .

HY-17447A

Tranylcypromine hydrochloride 4 Publications Verification SKF 385 hydrochloride
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 *(LSD1/BHC110)* and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .

HY-112304A

(1R,2S)-NCD38 TFA

Histone Demethylase Others

(1R,2S)-NCD38 TFA is an enantiomer of NCD38 TFA. NCD38 TFA is a LSD1-selective inhibitor .

(1R,2S)-NCD38 TFA	Histone Demethylase	Others
(1R,2S)-NCD38 TFA is an enantiomer of NCD38 TFA. NCD38 TFA is a *LSD1*-selective inhibitor .

HY-101075A

L-690330 hydrate	Phosphatase	Others
L-690330 hydrate is a competitive inhibitor of inositol monophosphatase (IMPase) with K_is of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 hydrate exhibits 10-fold more sensitive than mouse and rat IMPase .

HY-P4091

LSD

Fluorescent Dye Cancer

LSD is a conjugate with phthalocyanine dye for photoimmunoresearch research .

*LSD*	Fluorescent Dye	Cancer
LSD is a conjugate with phthalocyanine dye for photoimmunoresearch research .

HY-146380

S1427	Histone Demethylase	Cancer
S1427 is a tranylcypromine-derived *LSD1* inhibitor with the IC₅₀ of 390 nM and K_i of 80 nM. S1427 exhibits desirable hERG channel inhibition and microsomal stability profiles. Inhibition of LSD1 partially reduces the proliferation of cancer cells .

HY-151190

cis-4-Br-2,5-F2-PCPA S1024	Histone Demethylase	Cancer
cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 94 nM instead of 8.4 μM for *LSD2. There is aberrant expression of LSD1* in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits *LSD1* cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells .

HY-W025799

N-Benzylideneaniline

N-Benzalaniline; N-Phenylbenzylimine
Histone Demethylase Cancer

N-Benzylideneaniline is an inhibitor of xylinostilbene-α,β-dioxygenase (LSD) .

N-Benzylideneaniline N-Benzalaniline; N-Phenylbenzylimine	Histone Demethylase	Cancer
N-Benzylideneaniline is an inhibitor of xylinostilbene-α,β-dioxygenase (LSD) .

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride (1S,2R)-SKF 385-d₅ hydrochloride	Monoamine Oxidase	Neurological Disease
(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-15774A

CBB1003 hydrochloride

Histone Demethylase Cancer

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
HY-15774

CBB1003

Histone Demethylase Cancer

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003 hydrochloride	Histone Demethylase	Cancer
CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003	Histone Demethylase	Cancer
CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

HY-115747

Namoline	Histone Demethylase	Cancer
Namoline, a γ-pyrone, is a selective and reversible Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research .

HY-110130

RN-1 dihydrochloride	Histone Demethylase	Cardiovascular Disease Cancer
RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC₅₀ values of 0.51 μM and 2.785 μM respectively .

HY-12635

SP2509

5+ Cited Publications

Histone Demethylase Apoptosis Cancer

SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC₅₀ of 13 nM .

SP2509 5+ Cited Publications	Histone Demethylase Apoptosis	Cancer
SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC₅₀ of 13 nM .

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective *LSD1/KDM1A* inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research .

HY-103085

T-3775440 hydrochloride 2 Publications Verification	Histone Demethylase	Cancer
T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase *(LSD1)* inhibitor with an IC₅₀ value of 2.1 nM.

HY-117226A

GSK 690 Hydrochloride 1 Publications Verification	Histone Demethylase	Others
GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 *(LSD1), with a K_d* value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-117226

GSK 690

Histone Demethylase Cancer

GSK 690 is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2037A

Higenamine hydrochloride 1 Publications Verification Norcoclaurine hydrochloride	Structural Classification Classification of Application Fields Source classification Plants Lindera aggregata (Sims) Kosterm. Alkaloids Phenols Polyphenols Lauraceae Isoquinoline Alkaloids Disease Research Fields Endocrinology Cancer	MDM-2/p53 ROS Kinase Apoptosis
Higenamine hydrochloride is a selective *LSD1* inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

Cat. No.	Product Name	Chemical Structure

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-17447SA

Tranylcypromine-d5 hydrochloride

Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks